AstraZeneca buys ZS Pharma for $2.7 billion, pips Actelion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform
November 9, 2015 9:36 AM ESTLeerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.
Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More
JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral
November 9, 2015 7:17 AM ESTJPMorgan downgraded ZS Pharma (NASDAQ: ZSPH) from Overweight to Neutral with a price target of $90.00 (from $75.00).
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $89.04 yesterday.
... MoreCredit Suisse Downgrades ZS Pharma (ZSPH) to Neutral on Takeover
November 9, 2015 6:24 AM ESTCredit Suisse downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Neutral with a price target of $90.00 (from $67.00) after the company agreed to be acquired by AZN
For an analyst ratings summary and ratings history on ZS Pharma... More
William Blair Downgrades ZS Pharma (ZSPH) to Market Perform
November 6, 2015 2:23 PM ESTWilliam Blair downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $63.31 yesterday.
... MoreRelypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal
November 6, 2015 6:53 AM ESTRelypsa (NASDAQ: RLYP) shares are poised higher after AstraZeneca (NYSE: AZN) agreed to acquire ZS Pharma (NASDAQ: ZSPH) for $2.7 billion. Shares of Relypsa are set to open higher by 20%.
... MoreAstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM ESTAstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ionÂ-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition... More
